Plus Therapeutics Showcases CNS Cancer Diagnostics and Therapy Data at SNO/ASCO Conference
Event summary
- Plus Therapeutics will present two posters on its ReSPECT-LM clinical program and CNSide diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference (August 13–15).
- The company will host a sponsored symposium titled 'Redefining the Management of Leptomeningeal Metastases' on August 13.
- Plus Therapeutics will rebrand as Cerenome, Inc. and change its ticker to CNSY starting August 3, 2026.
The big picture
Plus Therapeutics is positioning itself as a key player in the growing field of precision diagnostics and targeted therapies for CNS cancers. The company's focus on integrating diagnostics with emerging treatments aligns with broader industry trends toward personalized medicine, particularly in oncology. With its upcoming rebrand to Cerenome, Plus aims to consolidate its role in this niche but expanding market segment.
What we're watching
- Clinical Validation
- How emerging data from the ReSPECT-LM program will impact regulatory and commercial prospects for REYOBIQ.
- Diagnostic Adoption
- Whether CNSide's economic impact analysis can accelerate reimbursement and adoption in leptomeningeal metastases management.
- Rebranding Strategy
- The pace at which Cerenome can establish itself as a leader in integrated CNS oncology solutions post-rebrand.
Related topics